TATA健康(01255) - 2025 - 中期业绩

Financial Highlights The company reported unaudited interim results for H1 2024, with revenue down 30.6% to HK$72,309 thousand, gross profit down 35.0% to HK$55,397 thousand, and loss attributable to owners narrowing to HK$5,130 thousand | Metric | | | For the six months ended June 30 | | | :--- | :--- | :--- | :--- | :--- | | | | | 2024 | 2023 | | Revenue | | HK$ thousand | 72,309 | 104,131 | | Gross profit | | HK$ thousand | 55,397 | 85,233 | | Loss before tax | | HK$ thousand | (5,130) | (14,290) | | Loss attributable to owners of the Company | | HK$ thousand | (5,130) | (12,327) | | Gross profit margin | | % | 76.6 | 81.9 | | Loss attributable to owners of the Company margin | | % | (7.1) | (11.8) | | — Loss per share | Basic and diluted | HK$ | (0.02) | (0.05) | Condensed Consolidated Financial Statements This section presents the unaudited condensed consolidated statement of profit or loss and other comprehensive income and financial position, showing decreased revenue, narrowed loss, and improved net liabilities Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income This statement details the company's financial performance, showing revenue, cost of sales, gross profit, other income, expenses, and the resulting loss for the period | Metric | Note | For the six months ended | | | :--- | :--- | :--- | :--- | | | | June 30, 2024 (HK$ thousand) | June 30, 2023 (HK$ thousand) | | Revenue | 3 | 72,309 | 104,131 | | Cost of sales | | (16,912) | (18,898) | | Gross profit | | 55,397 | 85,233 | | Other income | | 2,463 | 2,004 | | Other gains and losses | 5 | (5,539) | (961) | | Selling and distribution costs | | (24,838) | (37,508) | | Administrative expenses | | (31,389) | (61,987) | | Finance costs | | (1,224) | (1,071) | | Loss before tax | 6 | (5,130) | (14,290) | | Taxation | 7 | — | — | | Loss for the period | | (5,130) | (14,290) | | Other comprehensive income | | | | | Exchange reserve released on deconsolidation of overseas subsidiaries | | 1,448 | — | | Total comprehensive expense for the period | | (3,682) | (12,279) | | Loss for the period attributable to: | | | | | Owners of the Company | | (5,130) | (12,327) | | Non-controlling interests | | — | (1,963) | | Total | | (5,130) | (14,290) | | Total comprehensive expense for the period attributable to: | | | | | Owners of the Company | | (3,682) | (11,011) | | Non-controlling interests | | — | (1,268) | | Total | | (3,682) | (12,279) | | Loss per share Basic and diluted (HK$) | 9 | (0.02) | (0.05) | Condensed Consolidated Statement of Financial Position This statement provides a snapshot of the company's assets, liabilities, and equity at the end of the reporting period, highlighting changes in financial position | Metric | Note | As at June 30, 2024 (HK$ thousand) | As at December 31, 2023 (HK$ thousand) | | :--- | :--- | :--- | :--- | | Non-current assets | | | | | Property, plant and equipment | | 26,071 | 27,758 | | Investment properties | | 2,100 | 2,100 | | Loan to an associate | | 5,757 | 5,236 | | Deferred tax assets | | 2,852 | 3,804 | | Deposits and prepayments for life insurance policies | | 1,944 | 1,930 | | Lease deposits and prepayments | | 3,568 | 4,474 | | Total non-current assets | | 42,292 | 45,302 | | Current assets | | | | | Inventories | | 15,149 | 13,324 | | Trade and other receivables | 10 | 20,382 | 23,494 | | Loan to an associate | | 38,765 | 38,765 | | Pledged time deposits | | 21,223 | 21,223 | | Bank balances and cash | | 38,074 | 40,002 | | Total current assets | | 133,593 | 136,808 | | Current liabilities | | | | | Trade and other payables | 11 | 108,544 | 131,424 | | Contract liabilities | | 70 | 151 | | Amounts due to related companies | | 7,863 | 10,449 | | Loan from a related company | | 10,692 | 10,692 | | Lease liabilities | | 14,243 | 14,845 | | Other borrowings — due within one year | | 15,000 | 15,000 | | Tax payable | | 275 | 178 | | Total current liabilities | | 156,687 | 182,739 | | Net current liabilities | | (23,094) | (45,931) | | Total assets less current liabilities | | 19,198 | (629) | | Non-current liabilities | | | | | Employee benefit obligations | | 1,665 | 1,665 | | Lease liabilities | | 11,224 | 13,878 | | Total non-current liabilities | | 12,889 | 15,543 | | Net assets / (liabilities) | | 6,309 | (16,172) | | Capital and reserves | | | | | Share capital | | 2,428 | 2,428 | | Reserves | | (4,389) | (707) | | Equity attributable to owners of the Company | | (1,961) | 1,721 | | Non-controlling interests | | 8,270 | (17,893) | | Total equity | | 6,309 | (16,172) | Notes to the Condensed Consolidated Financial Statements This section details the basis of preparation, accounting policies, segment information, revenue, taxation, loss per share, receivables/payables, and post-reporting events, including going concern uncertainties 1. Basis of Preparation This section outlines the accounting standards used for financial statement preparation, addresses issues of lost records, and discusses the company's going concern uncertainties - The consolidated financial statements are prepared in accordance with Hong Kong Financial Reporting Standards issued by the HKICPA, and include applicable disclosures required by the Listing Rules of the Stock Exchange of Hong Kong Limited and the Hong Kong Companies Ordinance[9] - After the retirement of former executive director Mr. Yang Jun, the company was unable to locate certain books, records, and supporting documents for Shang Ying International Group and Shang Ying Retail Group[10][11] - For financial statement preparation, the directors decided to consolidate the carrying amounts of assets and liabilities, and the results and cash flow data of Shang Ying International Group and Shang Ying Retail Group for the six months ended June 30, 2023[12] - The company's shares have been suspended from trading since April 2, 2024, with limited working capital. The Group has entered into an agreement to dispose of its financial services business (Shang Ying Capital Group), but its books and records are considered inadequate[12][13] - Shang Ying Internet Medical (Shanghai) Co., Ltd. had its bankruptcy liquidation application accepted on April 29, 2024, and a liquidator appointed on May 6, leading to the Company losing control and deconsolidating it from that date[14] - As of the end of the reporting period, the Group recorded a net loss of approximately HK$5,130 thousand (2023: HK$14,290 thousand), with current liabilities exceeding current assets by approximately HK$23,094 thousand, and total liabilities exceeding total assets by approximately HK$998 thousand[15] - The Board believes that, considering the HK$50,000 thousand financial support from non-executive director Mr. Zhang Mingqi and the derecognition of certain subsidiary liabilities, the Group will have sufficient working capital to continue as a going concern[15] - Despite these plans, the outcome of management's efforts to address significant doubts about the going concern ability remains uncertain, thus a material uncertainty exists regarding the Group's ability to continue as a going concern in the foreseeable future[16] 2. Principal Accounting Policies This section details the accounting policies applied in the condensed consolidated financial statements, including the adoption of new and revised HKFRSs - The condensed consolidated financial statements are prepared on a historical cost basis, using the same accounting policies and methods of computation as the 2023 annual financial statements, except for the application of certain revised Hong Kong Financial Reporting Standards[17] - Several revised Hong Kong Financial Reporting Standards were first applied in this interim period, including lease liabilities in sale and leaseback transactions and classification of liabilities as current or non-current, but had no significant impact on financial position or performance[18] - New and revised Hong Kong Financial Reporting Standards that have been issued but are not yet effective are listed, and are not expected to have a significant impact on the Group's current and prior period financial position, performance, and/or disclosures[19] 3. Revenue This section provides a breakdown of revenue by source, sales channel, and timing of recognition for the reporting periods Disaggregation of Revenue from Contracts with Customers | Revenue Source | June 30, 2024 (HK$ thousand) | June 30, 2023 (HK$ thousand) | | :--- | :--- | :--- | | Footwear products | 72,309 | 100,660 | | Health products | — | — | | Financial services | — | 3,369 | | Online medical services | — | 102 | | Total | 72,309 | 104,131 | Sales Channels | Sales Channel | June 30, 2024 (HK$ thousand) | June 30, 2023 (HK$ thousand) | | :--- | :--- | :--- | | Retail | 70,281 | 98,466 | | Wholesale | 2,028 | 2,194 | | Internet | — | 102 | | Corporate | — | 3,369 | | Total | 72,309 | 104,131 | Timing of Revenue Recognition | Timing of Recognition | June 30, 2024 (HK$ thousand) | June 30, 2023 (HK$ thousand) | | :--- | :--- | :--- | | At a point in time | 72,309 | 100,660 | | Over time | — | 3,471 | | Total | 72,309 | 104,131 | 4. Operating Segments This section presents financial information segmented by business activities and geographical regions, detailing external sales and segment results - The Group's reportable segments include trading of footwear products, trading of health products, financial services, and online medical services[25] Segment Revenue and Results for the Six Months Ended June 30, 2024 | Segment | External Sales (HK$ thousand) | Segment Results (HK$ thousand) | | :--- | :--- | :--- | | Trading of footwear products | 72,309 | 2,428 | | Trading of health products | — | — | | Financial services | — | — | | Online medical services | — | — | | Total segments | 72,309 | 2,428 | | Unallocated income | | 584 | | Unallocated expenses | | (8,142) | | Loss before tax | | (5,130) | Segment Revenue and Results for the Six Months Ended June 30, 2023 | Segment | External Sales (HK$ thousand) | Segment Results (HK$ thousand) | | :--- | :--- | :--- | | Trading of footwear products | 100,660 | (1,254) | | Trading of health products | — | (697) | | Financial services | 3,369 | 360 | | Online medical services | 102 | (4,457) | | Total segments | 104,131 | (6,048) | | Unallocated income | | 978 | | Unallocated expenses | | (9,220) | | Loss before tax | | (14,290) | Geographical Information | Region | June 30, 2024 (HK$ thousand) | June 30, 2023 (HK$ thousand) | | :--- | :--- | :--- | | Hong Kong | 64,592 | 95,061 | | Australia | — | — | | Macau | 7,717 | 8,968 | | Mainland China | — | 102 | | Total | 72,309 | 104,131 | 5. Other Gains and Losses This section details the components of other gains and losses, including net exchange gains/losses and loss on deconsolidation of a subsidiary Other Gains and Losses | Item | June 30, 2024 (HK$ thousand) | June 30, 2023 (HK$ thousand) | | :--- | :--- | :--- | | Net exchange (gain) / loss | 7 | (961) | | Loss on deconsolidation of a subsidiary | (5,554) | — | | Gain on disposal of property, plant and equipment | 8 | — | | Total | (5,539) | (961) | 6. Loss Before Tax This section itemizes expenses and income deducted from or credited to loss before tax, such as depreciation and staff costs Items Deducted From / (Credited to) Loss Before Tax | Item | June 30, 2024 (HK$ thousand) | June 30, 2023 (HK$ thousand) | | :--- | :--- | :--- | | Depreciation of property, plant and equipment | 8,033 | 6,042 | | Premiums for life insurance policies | 15 | 13 | | Staff costs, including directors' emoluments | 21,608 | 39,130 | | Reversal of provision for inventories (credited to cost of sales) | (10,520) | (13,177) | | Cost of inventories recognised as an expense (including net reversal of provision for inventories) | 16,912 | 18,898 | 7. Taxation This section explains the tax treatment across different jurisdictions, noting no tax provision due to tax losses or lack of taxable profits - The Company, incorporated in the Cayman Islands, along with Group entities incorporated in the British Virgin Islands, had no taxable profits in either period[30] - Hong Kong profits tax is calculated under a two-tiered profits tax rate regime, but no provision for Hong Kong profits tax was made as the Group's carried forward tax losses were sufficient to offset estimated taxable profits for the current year[31] - No provision was made for Macau complementary tax, Taiwan income tax, and PRC enterprise income tax as the relevant entities had no taxable profits in either period[31][32] 8. Dividends This section confirms that no dividends were paid, declared, or proposed during the interim period - No dividends were paid, declared, or proposed during the interim period, and the Board decided not to pay dividends for the interim period[33] 9. Loss Per Share This section details the calculation of basic and diluted loss per share based on the loss attributable to owners and weighted average shares Loss Per Share Calculation | Metric | June 30, 2024 | June 30, 2023 | | :--- | :--- | :--- | | Loss for the period attributable to owners of the Company (HK$ thousand) | 5,130 | 12,327 | | Weighted average number of ordinary shares (thousand shares) | 242,845 | 242,845 | | Basic and diluted loss per share (HK$) | (0.02) | (0.05) | 10. Trade and Other Receivables This section outlines credit terms for sales and provides an aging analysis of trade receivables - Credit terms for retail sales of footwear products range from 30 to 60 days, while for wholesale footwear products, trading of health products, and financial services, credit terms range from 30 to 90 days[35] Aging Analysis of Trade Receivables | Aging | June 30, 2024 (HK$ thousand) | December 31, 2023 (HK$ thousand) | | :--- | :--- | :--- | | Within 30 days | 2,734 | 8,398 | | 31 to 60 days | 1,239 | 196 | | 61 to 90 days | — | 210 | | Over 90 days | 70 | — | | Total | 4,043 | 8,804 | 11. Trade and Other Payables This section specifies the average credit period for trade payables and presents their aging analysis - The average credit period for trade payables is 30 days[36] Aging Analysis of Trade Payables | Aging | June 30, 2024 (HK$ thousand) | December 31, 2023 (HK$ thousand) | | :--- | :--- | :--- | | Within 30 days | 1,709 | 2,769 | | 31 to 60 days | — | 215 | | 61 to 90 days | — | — | | Over 90 days | 1,700 | 1,677 | | Total | 3,409 | 4,661 | 12. Events After the Reporting Period This section details significant events occurring after the reporting period, including subsidiary bankruptcy liquidation and disposal agreements - Shang Ying Medical's bankruptcy liquidation application was accepted on April 29, 2024, and a liquidator was appointed on May 6, leading to the Company losing control over its assets and operations[37] - The Group completed the disposal of its subsidiary, Shang Ying International Group, to an independent third party in April 2025[37] - The Group entered into a sale and purchase agreement with an independent third party in September 2025 for the disposal of its subsidiary, Shang Ying Retail Group, which remains uncompleted as of the announcement date[38] - The Group entered into a sale and purchase agreement with an independent third party in September 2025 for the disposal of Shang Ying Capital Group, which remains uncompleted as of the announcement date[39] Management Discussion and Analysis This section reviews business performance and financial condition, noting declining footwear revenue and stagnant other services, outlining future strategies and challenges including going concern and foreign exchange risk Business Review and Future Developments This section reviews the performance of various business segments, highlighting the decline in footwear revenue and stagnation in other services, along with future strategic focuses - During the reporting period, the footwear business accounted for 100% of the Company's revenue, while health products and online medical services businesses remained stagnant[40] - Footwear business revenue was approximately HK$72,300 thousand, a 28.2% decrease from the same period last year, primarily due to weak consumer sentiment and ongoing economic uncertainty[41] - Health products business segment revenue was zero, mainly due to business stagnation[42] - Financial services business revenue was zero, primarily due to business stagnation, and DSG Securities (Hong Kong) Limited has applied to reduce its Type 1 regulated activity[43] - Online medical services business revenue was zero, mainly due to business stagnation and Shang Ying Medical entering bankruptcy proceedings[44] - Moving forward, the company will focus more on diversifying footwear products, exploring potential business collaborations, and introducing new brands with growth potential and high gross margins; DSG Group will continue to focus on developing its financing advisory business and exploring new market opportunities, such as Singapore[45] Financial Review This section provides a detailed financial overview, including revenue, cost of sales, gross profit, and key expense items, noting a narrowed loss before tax - The Group's revenue for the reporting period was approximately HK$72,300 thousand, a decrease of approximately 30.6% compared to the same period last year, mainly due to reduced footwear business revenue[46] - Footwear business revenue was approximately HK$72,300 thousand, a 28.2% decrease from the same period last year, with Hong Kong retail points decreasing to 27 and Macau increasing to 3[47] - Revenue from health products business, financial services business, and online medical services business was zero, primarily due to business stagnation[48][49][50] - Cost of sales was approximately HK$16,900 thousand, accounting for approximately 23.4% of revenue, a decrease from the same period last year, mainly due to reduced footwear product revenue[51] - Gross profit was approximately HK$55,400 thousand, a decrease of approximately 35.0% from the same period last year; gross profit margin was approximately 76.6%, a decrease[52] - Staff costs were approximately HK$21,600 thousand, accounting for approximately 29.9% of revenue, a decrease from the same period last year[53] - Depreciation accounted for approximately 11.1% of revenue, an increase from approximately 5.8% in the same period last year[54] - Finance costs were approximately HK$1,200 thousand, primarily comprising interest expenses arising from lease liabilities[55] - Loss before tax was approximately HK$5,100 thousand, a significant narrowing from approximately HK$14,300 thousand in the same period last year[56] Liquidity and Financial Resources This section discusses the company's funding sources, including internal cash flow, bank borrowings, and shareholder support, along with cash and short-term liabilities - The Group funds its operations with internally generated cash flow, bank borrowings, and financial support from the Company's shareholders[57] - As at June 30, 2024, bank balances and cash were approximately HK$38,100 thousand, a decrease of approximately 4.8% from December 31, 2023. Short-term other borrowings were approximately HK$15,000 thousand, and long-term lease liabilities were approximately HK$11,200 thousand[57] Pledge of Assets This section identifies specific assets pledged as collateral for bank borrowings and financing facilities - As at June 30, 2024, investment properties, land and buildings, deposits and prepayments for life insurance policies, pledged time deposits, and land and buildings of related companies were pledged to secure bank borrowings and banking facilities granted to the Group[58] Gearing Ratio This section presents the gearing ratio and explains its significant increase due to the reported loss Gearing Ratio | Metric | June 30, 2024 | December 31, 2023 | | :--- | :--- | :--- | | Gearing ratio (total liabilities divided by total equity) | 237.8% | -92.8% | - The gearing ratio increased significantly, primarily due to the Group recording a loss during the reporting period[59] Material Investments Held, Material Acquisitions or Disposals of Subsidiaries, Associates and Joint Ventures This section confirms the absence of material investments or significant acquisitions/disposals of subsidiaries, associates, or joint ventures during the reporting period - During the reporting period, the Group held no material investments, nor were there any material acquisitions or disposals of subsidiaries, associates, and joint ventures[60] Treasury Policy This section outlines the group's treasury policy aimed at controlling operations, reducing borrowing costs, and maintaining adequate cash levels - The Group's adopted treasury policy aims to improve control over its treasury operations and reduce borrowing costs, striving to maintain adequate levels of cash and cash equivalents[61] - The Board will consider various funding sources based on the Group's capital requirements to ensure financial resources are utilized in the most cost-effective and efficient manner, and will review and evaluate the treasury policy periodically[61] Announcements Made Pursuant to Rule 3.7 of the Takeovers Code This section details announcements regarding the appointment of receivers over pledged shares and the subsequent cessation of their appointment - On May 7, 2020, the Company received a letter regarding the appointment of joint and several receivers and managers over 123,993,617 shares of the Company (representing approximately 51.06% of the issued shares) held by Shang Ying Financial Holdings Limited, and the receivers may seek potential buyers for the pledged shares[62] - According to the monthly update announcement on July 22, 2025, the receivers ceased to be joint and several receivers and managers of the pledged shares effective June 2, 2025, and the offer period ended on the same day, as the Company believed an offer for the pledged shares was unlikely to materialize soon[63] Foreign Exchange Risk This section discusses the group's exposure to foreign exchange fluctuations from sales and purchases denominated in various currencies - The Group's sales and purchases during the reporting period were largely denominated in HK$, RMB, MOP, SGD, EUR, USD, and AUD, exposing it to foreign exchange fluctuation risks[64] - RMB is not freely convertible, and the MOP currency market is relatively small and undeveloped, with future exchange rates potentially influenced by government control, economic developments, and geopolitical changes[64] - The Group manages its foreign currency risk by closely monitoring foreign currency exchange rate movements and had not entered into any foreign currency forward contracts to hedge foreign currency risk as at June 30, 2024[64] Human Resources This section provides information on employee numbers, remuneration policies, and staff training initiatives - As at June 30, 2024, the Group employed 114 employees, a decrease from 130 employees as at December 31, 2023[65] - Remuneration packages are generally determined by reference to current market terms, individual qualifications, and experience, with various training activities conducted to enhance staff performance[65] Dividends This section reiterates the board's decision not to declare an interim dividend for the reporting period - The Board has resolved not to declare an interim dividend for the reporting period[66] Purchase, Sale and Redemption of the Company’s Listed Securities This section confirms that neither the company nor its subsidiaries purchased, sold, or redeemed any listed securities during the reporting period - Neither the Company nor any of its subsidiaries purchased, sold, or redeemed any of the Company's listed securities during the reporting period, nor did they hold any treasury shares[67] Other Information This section covers corporate governance, directors' securities trading compliance, audit committee duties, post-reporting events, publication details, and the continued suspension of share trading Corporate Governance This section confirms the board's review and compliance with the Corporate Governance Code during the reporting period - The Board has reviewed the Company's corporate governance practices and is satisfied that the Company has complied with the code provisions in Part 2 of the Corporate Governance Code as set out in Appendix C1 to the Listing Rules throughout the reporting period[68] Compliance with the Model Code for Securities Transactions by Directors This section confirms that all directors have complied with the Model Code for Securities Transactions by Directors of Listed Issuers - The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules, and after specific enquiry with the directors, each confirmed compliance with the required standards throughout the reporting period[69] Audit Committee This section describes the Audit Committee's review of accounting policies, risk management, internal controls, and financial reporting for the period - The Company's Audit Committee, comprising three independent non-executive directors, has reviewed the Group's principal accounting policies adopted with management and discussed risk management, internal control systems, and financial reporting matters, including the unaudited consolidated financial statements for this reporting period[70] Material Events After the Reporting Period This section confirms no other material events occurred after the reporting period, beyond those disclosed in the notes to the financial statements - Save for the matters disclosed in Note 12 to the consolidated financial statements and above in this announcement, there were no other material events concerning the Group after the reporting period[71] Publication of Interim Results Announcement and Interim Report This section provides information on the publication of the interim results announcement and the upcoming interim report - This interim results announcement of the Company has been published on the website of the Stock Exchange and the Company's website. The Company's 2023 interim report will be despatched to the Company's shareholders and published on the aforementioned websites in due course[72] Acknowledgement This section expresses gratitude to the management, staff, shareholders, business partners, banks, and auditors for their support - The Board would like to express its gratitude to the Group's management and all staff for their tireless efforts and dedication, and also to its shareholders, business partners, collaborators, bankers, and auditors for their strong support to the Group[73] Continued Suspension of Trading This section informs shareholders and potential investors about the continued suspension of trading in the company's shares until resumption guidance is met - At the Company's request, trading in the Company's shares on the Stock Exchange was suspended from 9:00 a.m. on April 2, 2024, and will remain suspended until the resumption guidance is met[74] - Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company's securities[75]